March 2013 Newsletter

March 20, 2013:

Growth in IVT Injection Volume Slows Again in Fourth Quarter

Q4-2012 was the second consecutive quarter in which there was a slowdown in growth for retinal procedures.

March 20, 2013:

FDA Schedules Panel Meeting in April to Review B+L’s Accommodating Toric IOL

An FDA advisory panel has been scheduled for April 8 to consider Bausch + Lomb’s premarket approval application for the Trulign Toric accommodating IOL.

March 20, 2013:

Use of Alternative Glaucoma Treatments Grows in Fourth Quarter

The Glaukos iStent played a large role in this increase, as the device entered its second full quarter since its US launch.

March 20, 2013:

More Rx, an MGD Procedure & Emerging Economies Mean Growth for Dry Eye Market

Dry eye treatments and technologies are expected to generate global revenues of $2.4 billion in 2013, with that tally climbing to nearly $3.0 billion in 2018.

March 20, 2013:

New Retinal Surgical Devices will Drive Future Revenue Growth

Steady revenue growth of 5 percent is forecast for established retinal surgical devices over the next five years, but we look for new technologies to fuel growth of 6.6 percent overall.

March 20, 2013:

March 2013 News Briefs

Social media